• RemeGen published “Telitacicept for IgA Nephropathy: Final Two-Year Results of the Phase 3 TELIGAN Trial.”
• Telitacicept’s annualized eGFR slope was -0.6 mL/min/1.73 m² over 104 weeks.
• The between-group slope difference favored telitacicept by 5.1 mL/min/1.73 m² annually (95% CI, 3.5–6.7; P<0.001).
• Urine protein-to-creatinine ratio reached 0.40 times baseline with telitacicept versus 1.01 with placebo.
• Serious treatment-emergent adverse events occurred in 8.2% of telitacicept patients versus 18.2% receiving placebo.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RemeGen Co. Ltd. published the original content used to generate this news brief on October 23, 2026, and is solely responsible for the information contained therein.